文献速递临床免疫分子诊断质量管理与危急值

全自动化学发光酶免疫法检测HBcrAg组分及磷酸化与非磷酸化HBcAg的临床意义

Evaluation of fully automated chemiluminescent enzyme immunoassays for hepatitis B core-related antigen components, phosphorylated and non-phosphorylated hepatitis B core antigens: clinical significance and dynamics during hepatitis B e antigen seroconversion.
PubMed 文献 · J Clin Microbiol · 2025-08-19

该研究开发了针对HBcAg和磷酸化HBcAg(pHBcAg)的全自动化学发光酶免疫法(CLEIA),cutoff分别为2.50和2.10 LogU/mL,并在100份血浆样本中观察到各组分强相关(r=0.896-0.970)。在HBeAg血清学转换面板及102例接受核苷(酸)类似物治疗的HBV感染者中,HBcAg与pHBcAg呈现不同动态变化,提示其可作为监测肝内HBV活性和疗效的独立生物标志物。

要点

  • HBcAg与pHBcAg的CLEIA cutoff分别为2.50和2.10 LogU/mL。
  • HBcAg与pHBcAg在核苷(酸)类似物治疗中显著下降但模式不同。
  • pHBcAg是高密度组分及空病毒颗粒中的主要成分。

核心结论

  • HBcAg、pHBcAg与HBcrAg在血清学转换和治疗中呈现不同动态,可作为监测肝内HBV活性和疗效的独立生物标志物。

研究设计与样本

  • 开发针对HBcAg和pHBcAg的全自动CLEIA,并评估其性能与临床相关性。
  • 使用100份市售血浆样本分析组分间相关性。
  • 使用HBeAg血清学转换面板分析HBcrAg组分动态。
  • 纳入102例接受核苷(酸)类似物治疗的HBV感染者血清样本评估临床相关性。

主要发现

  • HBcAg与pHBcAg的cutoff分别为2.50和2.10 LogU/mL。
  • 100份血浆样本中各组分间呈强相关(r=0.896-0.970)。
  • 核苷(酸)类似物治疗中HBcAg与pHBcAg水平均显著下降,但模式不同,提示存在不依赖HBV DNA的HBV活性及源自pc-mRNA的持续性HBcrAg组分。
  • OptiPrep密度梯度超速离心显示pHBcAg是高密度组分中的主要成分。
  • 免疫沉淀和Western blotting证实HBcAg组分主要被HBsAg包膜,pHBcAg是空病毒颗粒的主要成分。

关键数值与推荐

  • HBcAg的CLEIA cutoff为2.50 LogU/mL。
  • pHBcAg的CLEIA cutoff为2.10 LogU/mL。
  • 100份血浆样本中各组分间相关系数r=0.896-0.970。

临床怎么用

  • HBcAg和pHBcAg检测有望用于监测肝内HBV活性、免疫清除及非感染性病毒复制。
  • 将上述生物标志物纳入临床实践可能优化HBV管理策略、改善再激活风险预测并推进精准医学。

局限性

  • 原文指出研究存在样本量有限的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To assess the performance and clinical relevance of three assays-hepatitis B core-related antigen (HBcrAg), hepatitis B core antigen (HBcAg), and phosphorylated HBcAg (pHBcAg)-in quantifying HBcrAg, a critical biomarker of hepatitis B virus (HBV) infection, fully automated chemiluminescent enzyme immunoassays (CLEIA) for two HBcAg variants were developed. Cutoff values for HBcAg and pHBcAg assays were established at 2.50 and 2.10 LogU/mL, respectively. The strong correlations among components (r = 0.896-0.970) were observed by using purchased 100 plasma samples. When the dynamics of HBcrAg components were analyzed by using a series of hepatitis B e antigen (HBeAg) seroconversion panel, alongside correlations with HBV markers, distinct dynamics and molecular profiles were observed. For the assessment of the clinical relevance of these assays, serum samples were obtained from 102 HBV-infected patients treated with nucleos(t)ide analog (NA). Both HBcAg and pHBcAg levels were significantly reduced during NA therapy, but in different patterns, suggesting HBV activity independent of HBV DNA and persistent HBcrAg components derived from pc-mRNA. OptiPrep density gradient ultracentrifugation analysis identified pHBcAg as the dominant component in high-density fractions. Immunoprecipitation and Western blotting confirmed that HBcAg components were predominantly enveloped by hepatitis B surface antigen (HBsAg), with pHBcAg identified as the major component of empty viral particles. Although the limitation in sample size in this study, the revealed distinct dynamics of HBcAg, pHBcAg, and HBcrAg during seroconversion and treatment suggest these assays could serve as independent biomarkers for monitoring intrahepatic HBV activity and treatment efficacy.IMPORTANCEThis study evaluates novel fully automated chemiluminescent enzyme immunoassay (CLEIA) systems for hepatitis B core antigen (HBcAg) and phosphorylated HBcAg (pHBcAg) and identifies pHBcAg as the predominant component of hepatitis B virus (HBV)-derived empty viral particles, challenging previous assumptions and providing new insights into HBV biomarkers. HBcAg and pHBcAg show distinct dynamics in hepatitis B e seroconversion and nucleos(t)ide treatment from the other biomarkers including hepatitis B core-related antigen (HBcrAg), HBV RNA, and HBV DNA. The developed CLEIA systems for HBcAg and pHBcAg show promise as tools for monitoring intrahepatic HBV activity, immune clearance, and noninfectious viral replication. Incorporating these biomarkers into clinical practice could refine HBV management strategies, improve reactivation risk prediction, and advance precision medicine approaches.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Suzuki T, Ohue C, Arai O, et al. Evaluation of fully automated chemiluminescent enzyme immunoassays for hepatitis B core-related antigen components, phosphorylated and non-phosphorylated hepatitis B core antigens: clinical significance and dynamics during hepatitis B e antigen seroconversion. J Clin Microbiol. 2025. PMID: 40827906. doi:10.1128/jcm.00385-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。